Lecap Asset Management Ltd. Buys New Position in Enovis Corporation $ENOV

Lecap Asset Management Ltd. bought a new stake in Enovis Corporation (NYSE:ENOV) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 11,803 shares of the company’s stock, valued at approximately $370,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC raised its position in shares of Enovis by 266.7% in the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock valued at $27,000 after buying an additional 536 shares during the last quarter. GAMMA Investing LLC boosted its position in Enovis by 144.8% during the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock worth $45,000 after acquiring an additional 692 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in Enovis by 57.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company’s stock worth $74,000 after acquiring an additional 725 shares during the period. Cullen Frost Bankers Inc. acquired a new position in Enovis in the 1st quarter valued at $198,000. Finally, McIlrath & Eck LLC lifted its stake in shares of Enovis by 52.2% during the 1st quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock worth $202,000 after purchasing an additional 1,808 shares during the period. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ENOV has been the subject of a number of recent analyst reports. Needham & Company LLC lowered their price objective on Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Canaccord Genuity Group reduced their target price on Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Wells Fargo & Company decreased their price target on Enovis from $48.00 to $41.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. UBS Group dropped their price objective on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a report on Saturday, September 27th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Enovis has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Insider Transactions at Enovis

In other Enovis news, CEO Damien Mcdonald acquired 6,457 shares of the company’s stock in a transaction dated Thursday, September 11th. The stock was bought at an average price of $30.97 per share, with a total value of $199,973.29. Following the completion of the transaction, the chief executive officer directly owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. The trade was a 6.71% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Phillip Benjamin (Ben) Berry bought 2,500 shares of the business’s stock in a transaction dated Wednesday, August 20th. The stock was acquired at an average cost of $29.71 per share, for a total transaction of $74,275.00. Following the purchase, the chief financial officer owned 116,729 shares in the company, valued at approximately $3,468,018.59. This trade represents a 2.19% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 12,157 shares of company stock valued at $374,760 over the last 90 days. Corporate insiders own 2.70% of the company’s stock.

Enovis Stock Performance

Shares of NYSE:ENOV opened at $32.02 on Friday. The business has a 50-day moving average of $30.09 and a two-hundred day moving average of $32.13. The firm has a market capitalization of $1.83 billion, a PE ratio of -2.25 and a beta of 1.69. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. Enovis Corporation has a 12 month low of $25.47 and a 12 month high of $49.83.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The business had revenue of $564.50 million during the quarter, compared to analysts’ expectations of $555.80 million. During the same quarter in the previous year, the business earned $0.62 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. As a group, research analysts forecast that Enovis Corporation will post 2.79 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.